Brief: Astrazeneca Pharma India Surrenders Marketing Authorisation For Olaparib Tablets
15/04/2025 07:32
April 15 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS: SURRENDERS MARKETING AUTHORISATION FOR OLAPARIB TABLETS DISCONTINUATION DUE TO COMMERCIAL REASONS, NOT EFFICACY OR SAFETY HOLDS ALL OTHER PERMISSIONS FOR OLAPARIB IN INDIA NEVER MARKETED OLAPARIB INDICATION IN INDIA Source text: ID:nBSE1YlFfg Further company coverage: ASTR.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Astrazeneca Pharma India
See all newsBrief: Astrazeneca Pharma Gets Permission To Import For Sale Of Trastuzumab Deruxtecan
India's Astrazeneca Pharma logs worst slide in two months on quarterly profit drop
Brief: Astrazeneca Pharma India March-Quarter PAT 448.8 Million Rupees
Brief: Astrazeneca Pharma India Recommends Dividend Of 36 Rupees Per Equity Share For Fy2025-26
Brief: Astrazeneca Pharma India Receives Permission To Import Durvalumab (Imfinzi) For Additional Indication